Company / Working Capital
Elicio Therapeutics, Inc. Working Capital History
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$45.1M
FY2022
5-year range
$45.1M / $80.0M
FY2021-FY2022
Trend
-43.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$45M in FY2022.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, working capital decreased 43.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.36 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $45.1M | -43.6% |
| FY2021 | $80.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026